 AIkido Pharma Incorporated Nasdaq: AIKI today announced that it has secured an exclusive world-wide license for a broad spectrum antiviral drug platform. The licensed technology is a broadly acting pan-viral inhibitory compound with efficacy against multiple viral pathogens. The technology works to inhibit replication of multiple viruses including Influenza virus, SARS-COV coronavirus, MERS-COV, Ebolavirus and Marburg virus. 